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Abstract
22q11.2 deletion syndrome (22q11DS) results from a hemizygous deletion that typically spans 46 protein-coding genes and
is associated with widespread alterations in brain morphology. The specific genetic mechanisms underlying these
alterations remain unclear. In the 22q11.2 ENIGMA Working Group, we characterized cortical alterations in individuals with
22q11DS (n = 232) versus healthy individuals (n = 290) and conducted spatial convergence analyses using gene expression
data from the Allen Human Brain Atlas to prioritize individual genes that may contribute to altered surface area (SA) and
cortical thickness (CT) in 22q11DS. Total SA was reduced in 22q11DS (Z-score deviance = −1.04), with prominent reductions
in midline posterior and lateral association regions. Mean CT was thicker in 22q11DS (Z-score deviance =+0.64), with focal
thinning in a subset of regions. Regional expression of DGCR8 was robustly associated with regional severity of SA deviance
in 22q11DS; AIFM3 was also associated with SA deviance. Conversely, P2RX6 was associated with CT deviance. Exploratory
analysis of gene targets of microRNAs previously identified as down-regulated due to DGCR8 deficiency suggested that
DGCR8 haploinsufficiency may contribute to altered corticogenesis in 22q11DS by disrupting cell cycle modulation. These
findings demonstrate the utility of combining neuroanatomic and transcriptomic datasets to derive molecular insights into
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Introduction
22q11.2 deletion syndrome (22q11DS) arises from the deletion of
a segment of chromosome 22 due to misalignment of low copy
repeats (LCR) during nonallelic homologous recombination. It
occurs in approximately 1 in 3000–4000 births and spans a ∼2.6
megabase (Mb) region that results in the hemizygous deletion
of 46 protein-coding genes in 85–90% of patients (Guna et al.
2015), with ∼10–15% of 22q11DS patients carrying a smaller,
nested deletion (McDonald-McGinn et al. 2015). 22q11DS is
associated with a broad phenotype that includes heart anoma-
lies, immune dysfunction, and high rates of neuropsychiatric
and neurodevelopmental disorders such as schizophrenia,
intellectual disability, and autism spectrum disorder (ASD; Jonas
et al. 2014; Schneider et al. 2014). Alterations in brain structure
and function are thought to contribute to the psychiatric
and developmental phenotypes frequently observed in the
disorder.
Indeed, it is now established that 22q11DS is associated
with widespread alterations in brain morphology. Early mag-
netic resonance imaging (MRI) studies reported whole brain
volumetric reductions in 22q11DS, with greater reductions in
midline regions, as well as in posterior relative to anterior
regions (Tan et al. 2009; Karayiorgou et al. 2010). However, as
cortical gray matter volume reflects the product of cortical
surface area (SA; i.e., area covered by the cortex) and cortical
thickness (CT; i.e., thickness of the 6 neocortical layers), which
appear to be determined through relatively independent genetic
and neurodevelopmental mechanisms (Panizzon et al. 2009;
Winkler et al. 2010; Chen et al. 2013; Grasby et al. 2020, but see
also Schmitt et al. 2018), recent studies have examined these
morphometric characteristics separately. Thus, brain volume
reductions in 22q11DS were recently found to be driven by
widespread reductions in SA (Sun et al. 2019). Conversely, CT
tends to be increased in 22q11DS, with focal thinning in only a
minority of regions. Overall, the magnitude of SA alterations in
22q11DS is roughly 2-fold the magnitude of CT alterations (Sun
et al. 2020). Importantly, while 22q11.2 deletions yield reduced
expression of the majority of genes within the locus (Stark et al.
2008; Jalbrzikowski et al. 2015; Lin et al. 2016; Gordon et al.
2019), all genes within the locus are not expected to contribute
equally to brain phenotypes in the disorder (Motahari et al.
2019). As neuroanatomic abnormalities are associated with
a range of neuropsychiatric and developmental phenotypes,
clarifying the individual genes underlying these abnormalities
may provide insight into molecular mechanisms that contribute
to broader psychiatric and developmental phenotypes in
22q11DS.
Leveraging comprehensive maps of gene expression in
the human brain offers one promising approach to identify
molecular mechanisms underlying neuroanatomic deviations in
22q11DS. Recent studies have used the Allen Human Brain Atlas
(AHBA), a transcriptomic dataset quantifying the expression
of over 20 000 genes across postmortem brain tissue from six
psychiatrically healthy individuals, to elucidate mechanisms
underlying cellular and neural circuit variation in healthy
individuals and in populations with neuropsychiatric and
neurodegenerative disorders (Fornito et al. 2019). By examining
the spatial convergence between brain phenotypes and gene
expression patterns, recent studies found that brain regions
that are closer in physical proximity (Hawrylycz et al. 2012) or
have functionally correlated activity (Richiardi et al. 2015) share
more similar transcriptomic expression patterns. Similarly, a
prominent rostro-caudal gradient of gene expression has been
found across the cortex (Bernard et al. 2012; Hawrylycz et al.
2012; Miller et al. 2014), which is thought to reflect the rostro-
caudal gradient of neurogenesis and cell composition in which
posterior brain regions have a higher density of neurons that
are smaller in size, while anterior regions tend to have a lower
density of neurons that are larger in size and spine density
(Cahalane et al. 2012; Charvet et al. 2015; Fornito et al. 2019). In
clinical populations, the pattern of structural dysconnectivity
in schizophrenia patients was spatially correlated with the
expression of 43 genes previously implicated in schizophrenia
by genome-wide association (Romme et al. 2017); regional
expression of the Parkinson’s risk gene, MAPT, was spatially
correlated with the topography of connectivity differences in
patients with Parkinson’s disease (Rittman et al. 2016); and
regional expression of transcriptionally down-regulated genes
in postmortem cortex of ASD patients was associated with
severity of CT deviation in ASD (Romero-Garcia 2019). Spatial
convergence analyses were also recently applied in a 16p11.2
deletion mouse model to identify genes within the locus that
may be causally related to structural brain changes associated
with the copy number variant (CNV; Kumar et al. 2018).
Thus, prior studies of neurodevelopmental, neuropsychiatric,
and neurodegenerative populations suggest that identifying
genes with expression patterns that are spatially correlated
with neuroimaging phenotypes can offer a useful strategy to
elucidate genetic drivers of altered brain structure and function.
Here, as part of the 22q11.2 Enhancing Neuroimaging Genet-
ics through Meta-Analysis (ENIGMA) Working Group (Thompson
et al. 2020), we therefore integrated neuroanatomic data from a
large multicenter cohort of 22q11DS individuals with molecu-
larly confirmed deletions spanning the full LCR A-D region and
transcriptomic data from the AHBA. By characterizing the spa-
tial convergence between regional expression of each individ-
ual 22q11.2 gene and the severity of morphometric alterations
within patients, we sought to systematically prioritize individual
genes within the 22q11.2 locus that may be causally related to




Structural MRI (sMRI) data from 386 22q11DS patients and 315
typical developing controls analyzed in a previously published
study from the 22q11DS ENIGMA working group (Sun et al.
2020) were used to derive measures of SA and CT deviance in
22q11DS for the current study. Briefly, in the original study,
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control data. FreeSurfer image processing software (version
5.3.0; http://surfer.nmr.mgh.harvard.edu) was used to process
1 mm3 T1-weighted structural images acquired with an MPRAGE
sequence. Quality control was implemented using validated and
standardized processing pipelines developed for the ENIGMA
consortium (Thompson et al. 2014, 2017; http://enigma.ini.u
sc.edu/protocols/imaging-protocols). Total intracranial volume
(ICV) and SA and CT measures for 68 cortical regions (34 per
hemisphere) were calculated based on the Desikan-Killiany
atlas. Group effects in this multisite 22q11DS cohort were
previously found to be highly consistent across sites (Sun et al.
2020).
The purpose of the current analysis was to examine whether
the regional expression patterns of individual genes in the
22q11.2 locus are associated with regional severity of SA or
CT deviance in 22q11DS patients. Consequently, our analyses
focused on a homogeneous sample of 22q11DS patients with the
full ∼2.6 Mb A-D deletion and the typical expression patterns
(i.e., in healthy individuals) of the corresponding genes within
this region, based on the AHBA. 22q11.2 deletion breakpoints
for each patient were determined using multiplex ligation-
dependent probe amplification (MLPA; Vorstman et al. 2006),
which is a polymerase chain reaction (PCR)-based assay that
can detect copy number deletions and duplications for up to
50 DNA probe sequences in one reaction. Due to its low cost,
high sensitivity and specificity, and medium throughput, it
is considered a gold standard method for CNV genotyping
in humans (Kerkhof et al. 2017). MLPA for the current study
was completed using the SALSA MLPA Probemix P250-B2
DiGeorge kit from MRC-Holland, which includes 29 probe
sequences within the 22q11.2 locus to discern between common
22q11.2 deletion subtypes. Sites or scanners with no 22q11DS
patients with a confirmed A-D deletion or corresponding
healthy control data were excluded from the current analyses,
leaving data from 232 22q11DS patients with confirmed A-D
deletions and 290 controls collected on 10 scanners across
8 sites for analysis. Regional SA measures were adjusted for
effects of age, sex, and site/scanner; different scanners were
treated as independent “sites.” Regional CT measures were
additionally adjusted for age2, based on significant nonlinear
effects of age previously found in most ROIs for CT (Sun et al.
2020).
Subject consent at each site was obtained according to the
Declaration of Helsinki, and study protocols were approved by
ethical committees at each institution. Detailed information on
the sample recruitment procedures, image acquisition param-
eters, and data processing are published elsewhere (Sun et al.
2020).
Gene Expression Data
AHBA transcriptomic data for 20 737 largely protein-coding
genes, registered to the Desikan-Killiany cortical atlas for
integration with FreeSurfer-based analyses, were obtained from
https://figshare.com/articles/A_FreeSurfer_view_of_the_cortica
l_transcriptome_generated_from_the_Allen_Human_Brain_Atla
s/1439749 (French and Paus 2015). The original AHBA assayed
the expression of 58 692 probes at a high spatial resolution,
using custom Agilent arrays in 3702 brain samples derived
from six healthy adults with no known neuropsychiatric or
neuropathological history (Hawrylycz et al. 2012). In the French
and Paus (2015) atlas, expression values from multiple probes for
a given gene were first averaged to yield one expression value
per gene per tissue sample. Each cortical brain tissue sample
was then mapped to the nearest Desikan-Killiany cortical region
based on its Montreal Neurological Institute coordinates, and
for each individual brain, the median expression value across
tissue samples mapping to a given Desikan-Killiany region was
calculated for each gene. The median expression level across
the six brains, per region, was then calculated for each of the
20 737 genes (see French and Paus 2015 for details). Because
expression levels expression levels were measured from left
hemisphere regions in all six brains, but only in two brains for
right hemisphere regions, all region-based analyses used only
left hemisphere regions.
To define protein-coding genes within the 22q11.2 locus,
coordinates for the 22q11.2 locus were obtained from genome-
wide studies of CNVs associated with schizophrenia (Marshall
et al. 2017) and ASD (Sanders et al. 2015). Marshall et al. (2017)
reported CNV borders in hg18; the UCSC LiftOver tool was
used to convert them to hg19. As the 22q11.2 locus defined
in these studies shared more than 90% overlap in basepairs
(bp), the final 22q11.2 boundaries were defined as the union
between those identified in these two studies (Forsyth et al.
2020). HGNC gene symbols for protein-coding genes within the
locus were retrieved from Ensembl using the BioMart package
in R (Durinck et al. 2009). Genes with mean log2 expression
levels > 5, averaged across brain regions, were considered brain
expressed, leaving 28 brain-expressed 22q11.2 protein-coding
genes for investigation. The consistency of the expression
of each 22q11.2 gene across the six donors, as defined by




Group differences in age and sex were assessed with a univariate
ANOVA and a chi-squared test, respectively.
Neuroanatomic Group Differences
To characterize neuroanatomic alterations in the 22q11DS
patients included in the present analyses, global and regional
SA and CT metrics were first adjusted for age, sex, and scanner
effects by conducting linear models with each neuroanatomic
metric set as the dependent variable and with age, sex, and
scanner set as independent variables, additionally including
age2 for CT measures (Sun et al. 2020). Residualized values for
each subject and neuroanatomic metric were retained from
the linear models. Group differences in covariate-adjusted total
SA and in mean CT were then examined using general linear
models with total SA or mean CT as the dependent variable
and group as the independent variable. Group differences
in covariate-adjusted SA and CT for each left hemisphere
region were similarly tested using general linear models.
This analysis flow was selected such that between-group
neuroanatomic analyses and spatial convergence analyses
were conducted on the same covariate-adjusted neuroanatomic
values. Group differences in regional neuroanatomic mea-
sures are shown corrected for multiple comparisons using
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Prioritizing 22q11.2 Genes Based on Spatial
Convergence of Gene Expression and Neuroanatomic
Deviance
To prioritize 22q11.2 genes that may be causally involved in SA or
CT alterations in 22q11DS, our primary analysis focused on cor-
relations between regional expression of each brain-expressed,
protein-coding 22q11.2 gene and regional deviance in SA and CT,
respectively. The neuroanatomic deviance of 22q11DS patients
compared with controls was first defined using Z-scores for each
covariate-adjusted regional measure of SA and CT. Normalized
deviance scores were utilized over raw group difference scores in
order to account for differences in the area or average thickness
of regions as they are defined in the Desikan-Killiany atlas (i.e.,
to avoid nonmeaningful larger deviance scores in regions that
are defined in the reference Desikan-Killiany atlas as covering
a greater number of voxels; Grothe et al. 2018). Thus, mean SA
and CT for each left hemisphere region were first calculated
for each group. Given the global tendency for 22q11DS patients
to show smaller SA overall, mean SA per region for 22q11DS
patients was subtracted from the mean for controls and divided
by the standard deviation for controls for each region to yield
a Z-score severity measure of 22q11DS SA deviance (SA) per
region. For CT, given the global tendency for 22q11DS patients to
show higher CT, mean CT per region for controls was subtracted
from mean CT scores for 22q11DS patients and divided by the
standard deviation for controls per region to yield a Z-score
severity measure of 22q11DS CT deviance (CT) per region.
Pearson’s correlation coefficients were then used to examine
spatial convergence in the expression of each brain-expressed,
protein-coding AHBA gene and regional variation in 22q11DS
SA and CT severity. Pearson’s correlations were used given
that SA, CT, and the expression of the majority of brain-
expressed, protein-coding AHBA genes (>75%) were normally
distributed across regions (Shapiro–Wilk Test P > 0.05) and that
these are continuous variables. Spearman’s (nonparametric)
correlations yielded highly similar results (see Supplementary
Information). Error in correlation coefficient estimates and 95%
confidence intervals were assessed with bootstrapping (i.e.,
resampling the 34 cortical regions 1000 times with replacement)
using the “boot” package in R. The ratio of the mean correlation
per gene to its bootstrap standard deviation (i.e., Z-score
correlation) was used to generate percentile ranks for all brain-
expressed, protein-coding genes indexed in AHBA (i.e., 10 344
genes) and to derive corresponding P-values based on this
empirical distribution of all Z-score correlations across the
AHBA. 22q11.2 genes with expression patterns that showed
positive spatial correlations with 22q11DS SA or CT severity
at extreme high-rank values relative to all brain-expressed,
protein-coding AHBA genes (PAHBA < 0.05) were considered
statistically significant (Forsyth et al. 2020; Seidlitz et al. 2020).
This analysis leverages the fact that the proximal conse-
quence of the 22q11.2 deletion is reduced expression of the
majority of deleted genes and assumes that greater severity of
neuroanatomic deviation in 22q11DS will be evident in regions
where potential causally related genes within the locus are
typically most highly expressed.
Prioritizing 22q11.2 Genes Based on Partial Least
Squares Regression
As a complementary approach to the above described primary
analysis that leveraged each individual gene and individual SA
and CT deviance score per region, we also examined whether
an alternate approach utilizing a partial least squares regres-
sion (PLSR) data reduction technique would prioritize similar
22q11.2 genes. This secondary analysis was implemented to test
the robustness of our primary findings to variation in analysis
techniques. Thus, PLSR identifies principal components based
on both the predictors (i.e., here, the expression of all brain-
expressed, protein-coding genes in AHBA) and the outcome (i.e.,
here, 22q11DS SA or CT severity) to maximally explain covari-
ance between predictors and the outcome (Wehrens and Mevik
2007). In imaging transcriptomic analyses utilizing PLSR, the first
principal component (PLS1) represents the linear combination
of gene weights with expression patterns that best predict the
neuroimaging measure across regions. PLSR has previously been
used to identify biological processes that are broadly associated
with spatial neuroanatomic deviance patterns in neuropsychi-
atric and neurodevelopmental populations (Whitaker et al. 2016;
Romero-Garcia 2019; Seidlitz et al. 2018; Morgan et al. 2019)
and is generally used in scenarios when prioritizing individ-
ual genes out of an a priori set of candidate genes is not the
primary analysis goal. Nevertheless, gene weights on the first
principal component of a given model can also be used to rank
genes with expression patterns that best predict neuroanatomic
alterations.
To examine the validity of PLS1 for our SA and CT models,
the significance of the variance explained by PLS1 for each
model was tested by permuting the outcome labels 10 000 times.
To establish gene rankings for PLS1 for each model, error in
estimating each gene’s PLS1 weight for the SA and CT models
was assessed by bootstrapping (i.e., resampling the 34 cortical
regions 1000 times with replacement). The ratio of the mean
loading weight of each gene to its bootstrap standard deviation
(i.e., Z-score loading) was used to generate percentile ranks for
all genes for their PLS1 loading relative to the distribution across
all brain-expressed, protein-coding genes in AHBA and derive
corresponding empirical P-values. Genes with extreme high-
rank values (PAHBA < 0.05) within this empirical distribution were
considered to load significantly on PLS1 for each model. This
empirical distribution was also used to prioritize 22q11.2 genes
within the PLSR approach. Finally, gene ontology (GO) analyses
examined whether all genes that loaded significantly on PLS1
for each model were enriched for specific biological pathways,
molecular functions, or cellular components using g:Profiler
(Reimand et al. 2016), with “moderate” hierarchical filtering (best
per parent) and a minimum query/term overlap size of 5 genes.
Only pathways with 10 to 2000 genes were included, and a cus-
tom background was set to all protein-coding, brain-expressed
AHBA genes.
Characterizing 22q11.2 Gene Prioritization Relative to
Top Genes in Random Gene-Lists
Given that the proximal consequence of 22q11.2 deletions is
reduced expression of genes within the locus, our analyses
focused on prioritizing individual genes within the locus that
are most likely to be causally related neuroanatomic alterations
in 22q11DS. Nevertheless, to contextualize the strength of the
correlations between the top 22q11.2 genes and SA or CT
severity in 22q11DS, we also generated 10 000 random lists of
28 brain-expressed, protein-coding AHBA genes. The correlation
Z-scores for the top 22q11.2 gene identified in the primary
22q11SDS SA or CT severity analyses, as well as the Z-score
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Mean ICV mm3 (SD)
Site
Cardiff 13 14.5 (1.63) 6 (0.46) 1 611 369 (169717) 4 13.8 (0.98) 3 (0.75) 1 480 271 (124686)
Maastricht 38 29.3 (9.62) 15 (0.39) 1 516 538 (213418) 22 30.9 (6.39) 9 (0.41) 1 168 910 (204887)
Newcastle 26 16.8 (3.3) 14 (0.54) 1 674 857 (158963) 10 17.7 (2.5) 7 (0.7) 1 557 987 (168824)
Penn 50 17.5 (3.22) 20 (0.4) 1 568 669 (197479) 40 17.2 (3.24) 17 (0.43) 1 487 143 (195030)
SUNY 19 20.5 (1.24) 8 (0.42) 1 586 112 (197158) 20 20.8 (2.25) 8 (0.4) 1 469 248 (247659)
Toronto1 14 42.4 (8.67) 4 (0.29) 1 559 165 (177790) 11 42.8 (7.28) 6 (0.55) 1 477 699 (168739)
UCDavis1 36 10.4 (2.45) 19 (0.53) 1 535 111 (148718) 23 10.6 (2.04) 10 (0.43) 1 459 221 (154963)
UCDavis2 49 10.8 (2.39) 23 (0.47) 1 561 956 (154247) 49 11.6 (2.56) 25 (0.51) 1 476 262 (183531)
UCLA1 29 14.3 (5.7) 16 (0.55) 1 405 071 (139465) 18 14.4 (5.44) 12 (0.67) 1 373 803 (147130)
UCLA2 16 13.3 (3.6) 5 (0.31) 1 476 150 (145493) 35 15.9 (8.09) 18 (0.51) 1 380 253 (165746)
Total Sample 290 17.8 (9.43) 130 (0.45) 1 547 984 (183491) 232 17.5 (9.12) 115 (0.50) 1 436 108 (198219)
for SA or CT severity, were compared with the distribution of
top correlation Z-scores or top PLSR Z-score loadings across the
10 000 lists of 28 random genes (PGENE-LIST).
Characterizing the Gene Targets of DGCR8
Deficiency–Induced Down-Regulated miRNAs
Given the prominent gene regulatory role of DGCR8 via
microRNA (miRNA) biogenesis, to follow up on spatial con-
vergence results between regional expression of DGCR8 and
22q11DS cortical SA severity, we characterized the gene
targets of miRNAs previously suggested to be down-regulated
in the cortex due to DGCR8 deficiency. Specifically, given that
cortical tissue derived directly from 22q11DS patients was not
available, we focused on miRNAs with significantly reduced
expression in prefrontal cortex (PFC) in a mouse model of
22q11DS, whose down-regulation was accounted for by DGCR8
deficiency (Stark et al. 2008). Down-regulated miRNA names
were converted from miRBase version 9.1 to miRBase version
21.0 nomenclature using miRNA Accession IDs, and the human
gene targets of the homologous human miRNAs were identified
using miRTarBase v7.0 (Chou et al. 2018). Gene targets of DGCR8
deficiency–induced down-regulated miRNAs were functionally
annotated using GO biological pathways, molecular functions,
and cellular components from g:Profiler (Reimand et al. 2016).
Gene targets were also tested for enrichment for lists of genes
expressed in specific cell types and specific human brain
regions during specific developmental periods (i.e., relative
to all other regions/developmental periods) using the Specific
Expression Analysis tool (http://genetics.wustl.edu/jdlab/csea-
tool-2/; Dougherty et al. 2010). See Supplementary Material for
details.
Results
22q11DS versus Control Differences
The 22q11DS and control groups were similar in age, F(1,520) =
0.18, P = 0.67, and sex, χ2 = 0.98, P = 0.32 (Table 1).
In line with the larger 22q11.2 ENIGMA study (Sun et al. 2020),
22q11DS patients had significantly lower total SA compared
with control subjects (22q11DS M = 34 665 mm2, SD = 10 172;
Control M = 44 437 mm2, SD = 9409; Z-score SA = −1.04),
F(1,520) = 129.30, P = 2.20 × 10−16, and higher mean CT (22q11DS
M = 3.16 mm, SD = 0.11; Control M = 3.09, SD = 0.11; Z-score
CT = +0.64), F(1,520) = 57.92, P = 1.29 × 10−13. Similar to the
larger 22q11.2 ENIGMA study, the normalized deviance of SA
reductions in 22q11DS was nearly 2-fold in effect size magnitude
compared with that for the CT increase in 22q11DS.
SA reductions in 22q11DS were widespread, with particularly
prominent reductions in midline posterior brain regions, includ-
ing the cuneus, precuneus, and lingual gyrus, as well as lateral
association regions including superior parietal cortex and rostral
middle frontal gyrus (Fig. 1A; Supplementary Table 1). Parallel
analyses adjusting for ICV identified similar regions of lower SA
in 22q11DS versus controls (Supplementary Table 2).
Regional CT differences were also similar to those found in
the previous 22q11.2 ENIGMA study, with the majority of regions
showing subtle increases in CT in 22q11DS that were greatest in
frontal and parietal regions including rostral and caudal middle
frontal gyrus, medial and lateral orbitofrontal cortex, precen-
tral and postcentral gyrus, and supramarginal gyrus, as well
as in pericalcarine cortex and insula (Fig. 1D; Supplementary
Table 3). Significant focal thinning in 22q11DS was found in
the caudal anterior cingulate, superior temporal cortex, and
parahippocampus.
Prioritized Genes Associated with Neuroanatomic
Alterations in 22q11DS
Spatial correlation analyses comparing the expression patterns
of 22q11.2 genes to SA severity in 22q11DS revealed a signifi-
cant positive correlation between regional expression of DGCR8
and regional SA severity, Pearson r = 0.53, and PAHBA = 0.006
(Fig. 1A–C; Table 2). AIFM3 expression was additionally associ-
ated with SA severity, Pearson r = 0.42, and PAHBA = 0.041. Thus,
brain regions with higher expression of DGCR8 and AIFM3 in
healthy individuals showed greater reductions in cortical SA
in 22q11DS (Supplementary Fig. 1). Parallel analyses using SA
measures additionally adjusted for ICV, as well as those using
Spearman’s correlations, yielded highly similar results (Supple-
mentary Tables 4 and 5, respectively).
Parallel analyses for CT revealed that the spatial pattern
of CT severity in 22q11DS was significantly associated
with regional expression of P2RX6, r = 0.43, and PAHBA = 0.022
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Figure 1. Variation across 34 left hemisphere cortical regions in: A) Z-score surface area deviance (SA) severity in 22q11DS patients relative to controls (higher Z-score
indicates region with greater reduction in SA in 22q11DS); B) DGCR8 expression; C) AIFM3 expression; D) Z-score cortical thickness deviance (CT) severity in 22q11DS
relative to controls (higher Z-score indicates region with greater increase in CT in 22q11DS); and E) P2RX6 expression. Expression of DGCR8 and AIFM3 were significantly
associated with SA in 22q11DS and expression of P2RX6 was significantly associated with CT in 22q11DS.
higher P2RX6 expression in healthy individuals showed greater
increases in CT among 22q11DS patients compared with healthy
controls. Analyses using Spearman’s correlations yielded similar
results (Supplementary Table 6).
Restricting analyses to only brain-expressed, protein-coding
genes that were consistently expressed across the 6 AHBA
donors (average donor-to-median expression ρ > 0.446, as
defined by French and Paus (2015); 4947 genes) included 16
22q11.2 genes and similarly identified significant associations
between regional expression of DGCR8 and SA severity in
22q11DS (Supplementary Table 7) and regional expression of
P2RX6 with CT severity (Supplementary Table 8).
Robustness of Neuroanatomic Deviance in 22q11DS
and Prioritized 22q11.2 Genes Across Age Subgroups
To examine the robustness of these relationships across
development, we carried out parallel analyses examining
group differences and gene expression spatial correlations
with SA and CT severity for 3 age subgroups in the 22q11.2
ENIGMA cohort: children (≤12 years; 22q11DS n = 75, HC n = 89),
adolescents (13–17 years; 22q11DS n = 67, HC n = 77), and adults
(≥18 years; 22q11DS n = 90, HC n = 124). The overall pattern
of neuroanatomic differences among 22q11DS patients was
highly similar for each age subgroup compared with the
overall 22q11DS sample (see Supplementary Tables 9 and 10,
respectively). Consistent with this, conducting an exploratory
omnibus linear model across age groups, including a CNV group
by age group interaction term revealed no significant CNV group
by age group interactions for any ROI (FDR corrected P-values
> 0.05), similar to findings in the larger ENIGMA cohort (Sun
et al. 2020). This suggests that neuroanatomic differences in SA
and CT in 22q11DS patients are largely established by childhood.
Exploratory spatial correlation analyses for each age group
separately revealed significant positive correlations between
the expression of DGCR8 and regional SA severity for all 3
age subgroups (Supplementary Table 11; r range: 0.47–0.54, all
PAHBAs < 0.02). Regional AIFM3 expression was significantly cor-
related with SA severity among children (r = 0.41, PAHBA = 0.029)
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1 DGCR8 0.53 0.52 (0.13) 0.21–0.72 4.03 0.994 0.006
2 AIFM3 0.42 0.41 (0.14) 0.11–0.64 2.95 0.959 0.041
3 SCARF2 0.30 0.30 (0.17) −0.07—0.6 1.78 0.833 0.167
4 CLDN5 0.27 0.26 (0.16) −0.06—0.54 1.62 0.807 0.193
5 DGCR2 0.23 0.23 (0.15) −0.07—0.51 1.56 0.796 0.204
6 P2RX6 0.22 0.22 (0.15) −0.10—0.53 1.44 0.778 0.222
7 TANGO2 0.22 0.22 (0.17) −0.13—0.53 1.31 0.755 0.245
8 RANBP1 0.13 0.13 (0.14) −0.16—0.37 0.92 0.688 0.312
9 HIRA 0.05 0.06 (0.16) −0.28—0.36 0.36 0.583 0.417
10 UFD1 0.03 0.02 (0.15) −0.28—0.29 0.14 0.545 0.455
11 ARVCF 0 0 (0.18) −0.38—0.35 0.02 0.525 0.475
12 COMT 0 −0.02 (0.19) −0.44—0.28 -0.12 0.498 0.502
13 MED15 −0.05 −0.06 (0.17) −0.39—0.31 -0.33 0.461 0.539
14 GNB1L −0.07 −0.06 (0.15) −0.34—0.24 -0.42 0.446 0.554
15 PRODH −0.11 −0.11 (0.18) −0.45—0.26 -0.62 0.407 0.593
16 SLC25A1 −0.15 −0.16 (0.18) −0.50—0.20 -0.88 0.355 0.645
17 MRPL40 −0.28 −0.28 (0.17) −0.59—0.07 -1.70 0.204 0.796
18 GP1BB −0.25 −0.25 (0.13) −0.50—0.04 -1.84 0.185 0.815
19 PI4KA −0.26 −0.26 (0.14) −0.50—0.02 -1.85 0.184 0.816
20 RIMBP3 −0.33 −0.32 (0.17) −0.62—0.04 -1.88 0.179 0.821
21 KLHL22 −0.30 −0.29 (0.15) −0.58—0.02 -1.96 0.166 0.834
22 RTN4R −0.32 −0.31 (0.15) −0.59—0.02 -2.09 0.146 0.854
23 C22orf39 −0.40 −0.38 (0.17) −0.67—0.04 -2.20 0.132 0.868
24 SEPT5 −0.39 −0.39 (0.15) −0.67—0.05 -2.51 0.095 0.905
25 DGCR6 −0.36 −0.36 (0.12) −0.59—0.10 -2.89 0.060 0.940
26 DGCR6L −0.45 −0.45 (0.13) −0.68—0.16 -3.37 0.031 0.969
27 SNAP29 −0.47 −0.46 (0.12) −0.67—0.19 -3.76 0.017 0.983
28 SLC7A4 −0.51 −0.51 (0.13) −0.74—0.21 -3.82 0.016 0.984
in adolescents (r = 0.39, PAHBA = 0.062; Supplementary Table 9).
Regional P2RX6 expression was significantly associated with
CT severity among adolescents (r = 0.41, PAHBA = 0.049) and
adults (r = 0.53, PAHBA = 0.012) and trended toward significance
among children (r = 0.28, PAHBA = 0.078; Supplementary Table 12).
GNB1L was also associated with CT severity in adolescents
(r = 0.41, PAHBA = 0.044).
Similar Prioritized 22q11.2 Genes Identified Using
Partial Least Squares Regression
Prioritizing 22q11.2 genes based on gene loadings on PLS1 for
the 22q11DS SA and CT models highlighted similar genes.
Thus, PLS1 for the SA model explained 26.7% of the covari-
ance between regional 22q11DS SA severity and gene expres-
sion, which was significantly more than expected by chance
(permutation P = 0.002). Among the 22q11.2 genes, DGCR8 and
AIFM3 loaded significantly on PLS1 (PAHBA < 0.05; Supplemen-
tary Table 13). Functional annotation of all genes with significant
loadings on PLS1 indicated that the spatial pattern of SA in
22q11DS was broadly associated with gene regulatory processes,
including transcriptional activity and chromatin organization
(Supplementary Fig. 3A).
PLS1 for the CT model explained 23.9% of the covariance
between regional 22q11DS CT severity and gene expression,
which was more than expected by chance (permutation
P = 0.003). Among 22q11.2 genes, P2RX6 loaded significantly
on PLS1 (PAHBA = 0.007; Supplementary Table 14). Functional
annotation of all genes with significant loadings on PLS1
indicated that the spatial pattern of CT in 22q11DS was broadly
associated with genes involved in transmembrane and ion
transmembrane transport (Supplementary Fig. 3B).
Characterizing 22q11.2 Gene Prioritization Relative to
Random Genome-Wide Gene-Lists
Relative to 10 000 lists of 28 random brain-expressed, protein-
coding AHBA genes, the strength of the relationship between
22q11DS SA severity and the correlation Z-score for the top
22q11.2 gene, DGCR8, was greater than the strongest association
observed in 85.9% of random gene-lists, PGENE-LIST = 0.141. For
22q11DS CT severity, the strength of the relationship with
the top 22q11.2 gene, P2RX6, was greater than 63.4% of lists,
PGENE-LIST = 0.366. The top 22q11.2 gene loading on PLS1 for
the 22q11DS SA model, DGCR8, was similarly greater than
for 94.8% of randomly generated gene-lists, PGENE-LIST = 0.052,
and the top 22q11.2 gene loading for PLS1 for the 22q11DS
CT model, P2RX6, was greater than for 83.4% of gene-lists,
PGENE-LIST = 0.166. The elevated but still modest ranking for the
strongest 22q11.2 gene spatial correlation with 22q11DS SA
and CT severity, respectively, compared with top correlations
identified among random sets of any 28 AHBA genes likely
reflects the fact that groups of genes work in concert to
carry out specific biological functions and, relatedly, that the
spatial expression patterns of many genes are highly correlated
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1 P2RX6 0.43 0.42 (0.12) 0.15–0.64 3.46 0.978 0.022
2 GNB1L 0.34 0.35 (0.13) 0.09–0.61 2.62 0.931 0.069
3 AIFM3 0.28 0.27 (0.17) −0.10—0.58 1.54 0.803 0.197
4 TANGO2 0.25 0.25 (0.17) −0.08—0.56 1.50 0.798 0.202
5 DGCR8 0.24 0.22 (0.16) −0.11—0.5 1.36 0.774 0.226
6 SCARF2 0.24 0.23 (0.17) −0.14—0.51 1.37 0.776 0.224
7 RANBP1 0.23 0.23 (0.14) −0.07—0.49 1.62 0.815 0.185
8 CLDN5 0.19 0.18 (0.14) −0.10—0.46 1.30 0.764 0.236
9 MRPL40 0.17 0.17 (0.14) −0.10—0.42 1.22 0.751 0.249
10 DGCR2 0.17 0.18 (0.18) −0.19—0.50 1 0.713 0.287
11 MED15 0.15 0.14 (0.17) −0.18—0.46 0.86 0.687 0.313
12 HIRA 0.11 0.10 (0.15) −0.19—0.38 0.67 0.649 0.351
13 KLHL22 0.09 0.10 (0.19) −0.27—0.47 0.52 0.622 0.378
14 RTN4R 0.05 0.05 (0.2) −0.3—0.45 0.25 0.557 0.443
15 COMT 0.04 0.04 (0.15) −0.30—0.30 0.25 0.558 0.442
16 ARVCF 0.01 0.01 (0.16) −0.31—0.33 0.05 0.507 0.493
17 UFD1 0.01 0.01 (0.17) −0.33—0.34 0.07 0.513 0.487
18 RIMBP3 -0.01 0 (0.18) −0.33—0.38 0.01 0.497 0.503
19 PI4KA -0.01 −0.01 (0.16) −0.33—0.31 −0.08 0.475 0.525
20 DGCR6L -0.10 −0.09 (0.17) −0.42—0.25 −0.52 0.378 0.622
21 SEPT5 -0.15 −0.14 (0.17) −0.44—0.19 −0.82 0.317 0.683
22 DGCR6 -0.20 −0.18 (0.15) −0.45—0.14 −1.22 0.243 0.757
23 GP1BB -0.22 −0.24 (0.16) −0.56—0.08 −1.46 0.203 0.797
24 PRODH -0.27 −0.26 (0.17) −0.55—0.11 −1.49 0.198 0.802
25 C22orf39 -0.28 −0.26 (0.16) −0.54—0.09 −1.61 0.177 0.823
26 SLC7A4 -0.31 −0.30 (0.16) −0.57—0.04 −1.90 0.134 0.866
27 SNAP29 -0.34 −0.33 (0.12) −0.53—0.08 −2.86 0.041 0.959
28 SLC25A1 -0.36 −0.36 (0.16) −0.64—0 −2.26 0.088 0.912
Characterizing Downstream Consequences of DGCR8
Haploinsufficiency
DGCR8 was the most prominent gene within the 22q11.2 locus
associated with SA severity in 22q11DS. Notably, DGCR8 is a
core component of the miRNA microprocessor complex involved
in the biogenesis of miRNAs, which are small noncoding
RNAs that critically regulate gene expression by binding
target messenger RNA (mRNA) transcripts to accelerate their
degradation or silence their translation into proteins. Given this
prominent gene regulatory role of DGCR8, to better understand
mechanisms through which DGCR8 haploinsufficiency may
contribute to SA in 22q11DS, we therefore explored whether
gene targets of miRNAs that are down-regulated in mouse PFC
due to DGCR8 deficiency (Stark et al. 2008) converge on specific
biological processes.
The 59 miRNAs down-regulated in PFC (Supplementary Table
15) due to DGCR8 deficiency targeted 6804 unique human genes
(Supplementary Table 16). GO analysis revealed that these genes
were enriched for biological processes that include regulation
of the cell cycle, cell response to stress, and gene expression
(Fig. 2A). DGCR8-down-regulated miRNA gene targets were sig-
nificantly enriched for genes expressed during fetal develop-
ment across brain regions (Fig. 2B) and were not associated with
any specific cell type (Fig. 2C), consistent with this biological
pathway enrichment profile. Expanding analyses to to addition-
ally include include gene targets of miRNAs down-regulated in
hippocampus due to DGCR8 deficiency (Stark et al. 2008; Earls
et al. 2012) yielded similar results (Fig. S4, Fig. S5).
Discussion
22q11DS is a rare genetic disorder characterized by neu-
roanatomic abnormalities that include widespread reductions
in cortical SA and thicker cortex overall, with focal thinning
in the caudal anterior cingulate, superior temporal cortex, and
parahippocampus. As the typically deleted 22q11.2 region (LCR
A-D) spans a gene-rich region, identifying which individual
genes underlie these neuroanatomic alterations has remained
a challenge. Here, by systematically examining the spatial
convergence between severity of cortical SA and CT deviation
in 22q11DS and expression of each 22q11.2 gene, we provide
novel evidence prioritizing DGCR8 as a potential contributor
to pervasive SA reductions in 22q11DS. AIFM3 was also
associated with 22q11DS SA reductions. Interestingly, P2RX6 was
associated with CT, suggesting that this gene may contribute
to increases in CT in individuals with 22q11DS. Notably, regional
expression of DGCR8 was robustly associated with severity of
SA in 22q11DS across all age subgroups examined, suggesting
that DGCR8 haploinsufficiency may disrupt early aspects of
corticogenesis that are established by childhood.
DGCR8 is essential for the biogenesis of miRNAs, which
regulate gene expression at the protein level (Rajman and
Schratt 2017), and has previously been suggested to play
a key role in 22q11DS phenotypes (Stark et al. 2008; Earls
et al. 2012; Merico et al. 2014; Eom et al. 2020; Forsyth et al.
2020). Specifically, DGCR8 forms a complex with Drosha to
cleave long primary miRNAs (pri-miRNAs) into short precursor
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Figure 2. Characterization of 6804 unique gene targets of 59 miRNAs down-regulated in mouse cortex due to DGCR8 deficiency. A) Top five significantly enriched
biological process, molecular function, and cellular component GO terms; B) enrichment for specific developmental periods and brain regions; and C) enrichment for
specific CNS cell types, defined at varying specificity indices using the Specific Expression Analysis tool (Dougherty et al. 2010). Varying specificity thresholds in (B)
and (C) are represented by the hexagon ring layers going from the least specific gene-lists (outer hexagons) to the most specific gene-lists (center), with hexagons
scaled to the size of the gene-lists. BH-corrected Fisher’s Exact p-values are plotted for each specificity threshold by color.
into mature miRNAs (∼22 nucleotides in length) by Dicer.
Mature miRNAs are then loaded into the RNA-induced silencer
complex (RISC), where they serve as a guide RNA strand for
binding target mRNA transcripts to silence their translation
into proteins. miRNA activity is increasingly recognized as a
powerful posttranscriptional gene regulatory mechanism for
diverse cellular processes, and in the brain, it is known to play
a particularly important role in regulating cell proliferation,
growth, and differentiation during fetal development (Yao et al.
2012; Rajman and Schratt 2017). Our finding that the gene
targets of miRNAs down-regulated in mouse cortex due to
DGCR8 deficiency are enriched for fetal-specific expression
and regulation of the cell cycle and cell proliferation is
consistent with these known roles of miRNAs. Notably, cell cycle
parameters govern the balance between stem cell proliferation
and differentiation during early brain development and thereby
critically modulate cortical size and structure (Rakic 2009).
In line with this, while knockout of DGCR8 is lethal, conditional
knockout of DGCR8 in mouse embryonic stem (ES) cells has been
found to disrupt cell cycle progression, ES cell proliferation, and
differentiation (Wang et al. 2007). Similarly, knockout of DGCR8
in neural progenitors was found to disrupt progenitor pool
maintenance, differentiation, and corticogenesis (Marinaro et al.
2017). Knockout of DGCR8 in pyramidal neurons also resulted
in severe microcephaly, cell loss, altered inhibitory synaptic
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hemizygous depletion of DGCR8 yields milder effects on miRNA
biogenesis relative to DGCR8 knockout, with some differences
in brain phenotypes (Marinaro et al. 2017), DGCR8+/− mice have
been found to have altered cell proliferation, neurogenesis, and
neuronal morphology (Stark et al. 2008; Fénelon et al. 2011; Ouchi
et al. 2013; Amin et al. 2017), as well as enlarged brain ventricular
volumes (Eom et al. 2020), altered homeostatic and synaptic
plasticity (Earls et al. 2012; Amin et al. 2017), and cognitive
deficits (Stark et al. 2008; Fénelon et al. 2011; Ouchi et al.
2013). Human induced pluripotent stem cell–derived neurons
with hemizygous DGCR8 loss also show changes in calcium
signaling and excitability (Khan et al. 2020). Our finding that
DGCR8 expression is robustly associated with severity of SA
deviation in 22q11DS across age subgroups is consistent with
this literature implicating DGCR8 as a key contributor to brain
and behavioral phenotypes in 22q11DS, and suggests that DGCR8
hemizygosity may contribute to SA reductions by disrupting
miRNA modulation of cell cycle regulation during early brain
development in 22q11DS.
AIFM3 was also associated with SA deviation in 22q11DS.
AIFM3 is a proapoptotic protein that appears to stimulate cell
death by depolarizing the membrane potential of mitochondria
and activating the classical caspase-dependent apoptotic cas-
cade (Xie et al. 2005; Zheng et al. 2019). Notably, in addition to
the fundamental role of cell cycle regulation in defining the size
and structure of the cortex, apoptosis also critically regulates
cortex size (Haydar et al. 1999). Thus, two prominent waves of
apoptosis are known to occur during corticogenesis. The first
wave involves the elimination of a large number of dividing
neuronal precursor cells during the peak of neurogenesis, regu-
lating the size of the neuronal precursor pool. The second wave
involves the elimination of postmitotic neurons during neu-
ronal migration, regulating the wiring of developing neuronal
networks (Blomgren et al. 2007). Although little is known about
the specific role of AIFM3 in brain development, AIFM3 is highly
expressed in the human brain (https://gtexportal.org/home/),
supporting the possibility that AIFM3 haploinsufficiency could
contribute to SA deficits by altering normal apoptotic processes
during corticogenesis.
Finally, P2RX6 was associated with CT deviation in 22q11DS.
P2RX6 encodes the P2X6 receptor—a member of the P2X-
purinergic family of ATP-gated ion channels that mediates
fast excitatory postsynaptic potentials in neurons and smooth
muscles (Motahari et al. 2019) and exerts neuromodulatory
functions (Khakh and North 2012). While little is known about
the role of P2RX6 during brain development, it is expressed
in both developing and adult brain and is alternately spliced
in the developing mouse brain and during in vitro neuronal
differentiation (da Silva et al. 2007). Although speculative, P2RX6
deficiency could contribute to CT abnormalities in 22q11DS
by altering modulation of synaptic signaling. Additional work
is needed to experimentally validate that P2RX6 deficiency
contributes to abnormalities in CT in 22q11DS and clarify
underlying mechanisms.
Some potential limitations to the present study should be
noted. First, our analyses are correlational in nature and assume
causal, independent effects of deficient expression of one or
more 22q11.2 genes on the regional severity patterns of SA
and CT alterations in 22q11DS. Although the 22q11.2 deletion is
known to yield significantly reduced expression of the majority
of genes in the region (Stark et al. 2008; Jalbrzikowski et al.
2015; Lin et al. 2016; Gordon et al. 2019), experimental validation
is necessary to confirm the present prioritization of DGCR8,
AIFM3, and P2RX6 as genes that may be causally related to
cortical alterations in 22q11DS. In addition, our analyses do not
address the possibility that interactions between genes within
the locus or with additional downstream interacting partners
may also contribute to neuroanatomic alterations in 22q11DS,
nor for the possibility that some brain abnormalities in 22q11DS
may arise in part as downstream consequences of abnormali-
ties in other organs, such as heart anomalies, which could be
mediated by hemizygosity of genes within the 22q11.2 locus
that are not expressed in brain (Schaer et al. 2009, 2010). In
line with this, the strongest correlations (e.g., for spatial con-
vergence between DGCR8 expression and SA) were moderate
in strength, indicating that some variability in regional SA and
CT deviance is not predicted by individual expression of these
genes, as captured by the AHBA. Whether this is due to mea-
surement error, interactions between genes and/or with down-
stream interacting partners, nonuniform effects of hemizygos-
ity of individual 22q11.2 genes on corticogenesis in different
brain regions, or other explanations remains to be determined.
Additionally, we lacked high spatial resolution gene expression
data from the developing human brain when SA and CT are
initially shaped. We therefore relied on spatial expression data
from the AHBA to derive insight into molecular mechanisms
underlying neuroimaging phenotypes in 22q11DS, similar to
other groups that have leveraged the AHBA to understand neu-
roanatomic abnormalities in neuropsychiatric, neurodevelop-
mental, and neurodegenerative disorders (Rittman et al. 2016;
Romme et al. 2017; Romero-Garcia 2019; Fornito et al. 2019).
Given these limitations, negative findings should be interpreted
with caution, and future studies using gene expression data
from developing brain samples collected at high spatial resolu-
tion will be important to confirm the present findings. Finally,
our exploratory analysis of down-regulated miRNA gene targets
due to DGCR8 hemizygosity was based on findings in postna-
tal cortical samples from 22q11.2- and DGCR8-deficient mouse
models; it would be ideal to examine down-regulated miRNAs
in cortex derived directly from individuals with 22q11DS or with
DGCR8-specific hemizygous mutations, particularly during early
corticogenesis. In the absence of such tissue, we nevertheless
believe it is useful to identify biological pathways associated
with gene targets of miRNAs previously identified as down-
regulated in cortex due to DGCR8 deficiency. Conversely, the
large sample of individuals with confirmed A-D deletions and
matched control subjects used to derive spatial measures of SA
and CT deviation is a relative strength of the present study.
In summary, by integrating comprehensive maps of genome-
wide gene expression in the human brain and neuroanatomic
data from the largest existing sample of 22q11DS individuals
with molecularly confirmed A-D deletions, we prioritized DGCR8
and AIFM3 as potential contributors to cortical SA alterations in
22q11DS, and P2RX6 as a potential contributor to CT alterations.
While DGCR8 deficiency has been found to modulate cell cycle
progression, neural progenitor differentiation, and corticogen-
esis in animal models (Wang et al. 2007; Marinaro et al. 2017;
Hoffmann et al. 2018), experimental validation is needed to
confirm that AIFM3 and P2RX6 deficiency yield abnormalities
in cortical SA and thickness, respectively. Nevertheless, DGCR8
and AIFM3 are involved in regulating two neurodevelopmental
processes thought to fundamentally modulate brain size and
structure (i.e., cell proliferation and apoptosis, respectively).
Our finding that systematic investigation of 22q11.2 genes
prioritized relatively understudied genes (i.e., AIFM3 and P2RX6)
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phenotypes (i.e., DGCR8), provides important opportuni-
ties to pursue novel mechanistic hypotheses in 22q11DS.
Together, these results demonstrate the utility of combin-
ing neuroanatomic and publicly available transcriptomic
datasets to derive mechanistic insights and prioritize indi-
vidual genes that may underlie neuroanatomic differences in
multigene CNVs.
Supplementary Material
Supplementary material can be found at Cerebral Cortex online.
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